Laurus Labs Limited — Capital/Financing Update 2024

Feb 17, 2024

==> picture [452 x 75] intentionally omitted <==

February 17, 2024

To The Corporate Relations Department BSE Limited Phiroz Jeejeebhoy Towers, 25thFloor, Dalal Street Mumbai – 400001 Code: 540222	To The Listing Department National Stock Exchange of India Limited, Exchange Plaza, Bandra Kurla Complex, Bandra (East) Mumbai – 400 051 Code: LAURUSLABS

Sub: Update on Investment in M/s. Immunoadoptive Cell Therapy Private Limited

Ref:

1. Disclosure under Regulation 30 of the SEBI (LODR) Regulations, 2015 dated May 31, 2023

2. Update on payment of Tranche-1 subscription amount to M/s. Immunoadoptive Cell Therapy Private Limited dated July 12, 2023

Dear Sirs,

This has reference to our disclosures dated May 31, 2023 and July 12, 2023 regarding the signing of definitive agreements to acquire additional stake of 7.24% (on fully diluted basis) in Immunoadoptive Cell Therapy Private Limited (lmmunoACT), an advanced cell and gene therapy company for a cash consideration of Rs. 80 Crores and update on payment of Tranche1 subscription amount to ImmunoACT respectively.

In this regard, we wish to update that the Company has paid the subscription amount of Rs. 32,00,75,184/- (Rupees Thirty Two Crores Seventy Five Thousand One Hundred and Eighty Four only) as “ Tranche 2 (Final) Subscription Amount”.

The Shareholding of the Company in ImmunoACT is 33.86% (on a fully-diluted basis).

This is for your information and record.

Yours faithfully, For Laurus Labs Limited

Digitally signed by VENKATESWAR VENKATESWAR REDDY REDDY GOGIREDDY GOGIREDDY Date: 2024.02.17 12:04:13 +05'30'

G. Venkateswar Reddy Company Secretary & Compliance Officer

==> picture [452 x 43] intentionally omitted <==